TUSTIN, Calif., January 24, 2025--(BUSINESS WIRE)--Sabra Health Care REIT, Inc. (NASDAQ: SBRA) announced today the tax treatment for its 2024 distributions. The following table summarizes, for income tax purposes, the nature of cash distributions paid:

Sabra Health Care REIT, Inc.

Common Stock (CUSIP # 78573L106)

Record
Date  Payable
Date  Distribution
per Share  Total
Ordinary
Dividends  Non-Qualified
Dividends  Qualified
Dividends  Non-Dividend
Distributions 02/13/2024  02/29/2024  $ 0.3000000   $ 0.2649911   $ 0.2649911   $ 0.0000000   $ 0.0350089  05/20/2024  05/31/2024   0.3000000    0.2649911    0.2649911    0.0000000    0.0350089  08/19/2024  08/30/2024   0.3000000    0.2649911    0.2649911    0.0000000    0.0350089  11/15/2024  11/29/2024   0.3000000    0.2649911    0.2649911    0.0000000    0.0350089  $ 1.2000000   $ 1.0599644   $ 1.0599644   $ 0.0000000   $ 0.1400356  100.00%    88.33%          11.67%

The 2024 Non-Qualified Ordinary Dividends are also reported on Form 1099-DIV, Box 5, Section 199A Dividends. Treasury Regulation §1.199A-3(c)(2)(ii) requires that shareholders hold their REIT shares for at least 45 days in order for the dividends to be treated as Section 199A Dividends. Shareholders should consult with their tax advisors to determine whether this requirement affects any portion of the dividends included in Box 5.

Pursuant to Treas. Reg. § 1.1061-6(c), the Company reports that for purposes of section 1061 of the Internal Revenue Code, the One Year Amounts Disclosure and the Three Year Amounts Disclosure are $0.00 with respect to direct and indirect holders of "applicable partnership interests".

About Sabra

Sabra Health Care REIT, Inc. (NASDAQ:SBRA), a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a "REIT") that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124305467/en/

Contacts

Investor & Media Inquiries: 1-888-393-8248 or [email protected]

View Comments